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Whereas the sympathetic nervous
system has a well-established role in blood pressure (BP) regulation,
it is not clear whether long-term levels of BP are affected by
parasympathetic function or dysfunction. We tested the hypothesis
that chronic blockade of the parasympathetic nervous system has
sustained effects on BP, heart rate (HR), and BP variability (BPV).
Sprague-Dawley rats were instrumented for monitoring of BP 22-h
per day by telemetry and housed in metabolic cages. After the rats
healed from surgery and a baseline control period, scopolamine
methyl bromide (SMB), a peripheral muscarinic antagonist, was
infused intravenously for 12 days. This was followed by a 10-day
recovery period. SMB induced a rapid increase in mean BP from 98
2 mmHg to a peak value of 108  2 mmHg on day 2 of the SMB
infusion and then stabilized at a plateau value of 3  1 mmHg
above control (P 0.05). After cessation of the infusion, the mean BP
fell by 6  1 mmHg. There was an immediate elevation in HR that
remained signiﬁcantly above control on the last day of SMB infusion.
SMB also induced a decrease in short-term (within 30-min periods)
HR variability and an increase in both short-term and long-term
(between 30-min periods) BPV. The data suggest that chronic periph-
eral muscarinic blockade leads to modest, but sustained, increases in
BP, HR, and BPV, which are known risk factors for cardiovascular
morbidity.
blood pressure; autonomic nervous system; parasympathetic nervous
system; blood pressure variability
THE AUTONOMIC NERVOUS SYSTEM maintains cardiovascular ho-
meostasis through the opposing effects of its parasympathetic
and sympathetic divisions on cardiac performance and through
a predominantly sympathetic control of the vasculature.
Whereas a sympathetic effect on blood pressure (BP) regula-
tion is well established (6), there is also evidence of an
involvement of the parasympathetic nervous system in hyper-
tension. This was ﬁrst suggested by Julius et al. (12) on the
basis of acute pharmacological experiments in young individ-
uals with borderline hypertension and a hyperkinetic circula-
tion. Subsequent studies have shown an attenuation of the
parasympathetic control of heart rate (HR) in hypertension (33)
and in a number of conditions predisposing to hypertension
such as ageing (27), obesity (1, 31), diabetes mellitus (3),
chronic renal failure (2), and physical inactivity (24). However,
it is not clear whether parasympathetic dysfunction may affect
basal BP levels or exacerbate the hypertensive state. In addi-
tion, since vagal dysfunction impairs the baroreﬂex control of
HR, parasympathetic dysfunction could promote an increase in
BP variability (BPV) (7), which has been shown to be an
independent cardiovascular risk factor (9).
The purpose of the present study was to test the hypothesis
that sustained blockade of the parasympathetic system would
lead to increased BP and BPV. To this end, we investigated the
effects of a 12-day administration of scopolamine methyl
bromide (SMB) in rats instrumented for monitoring of BP by
telemetry. SMB, a quaternary derivative of scopolamine, was
chosen because it is a muscarinic antagonist that does not
readily cross the blood-brain barrier (4) and thus avoids po-
tential confounding effects of central muscarinic antagonism
such as increased parasympathetic tone (18).
METHODS
Animal preparation. Male Sprague-Dawley rats (10–12 wk old,
weighing 390–400 g) supplied by the R. Janvier Center (France)
were used in this study. All protocols were approved by the State
Animal Committee. The rats were instrumented (under pentobarbital
anesthesia, 60 mg/kg ip) with a BP telemeter (model TA11-PA-C40,
Data Sciences International) for monitoring of aortic BP as described
previously (32). A catheter was also inserted in the left jugular vein
and connected to a syringe pump via a single channel swivel as
described previously (35), for continuous intravenous infusion of
isotonic saline (10 l/min) starting on the day of surgery and main-
tained throughout the experimental study. The rats were housed in
individual Plexiglas cages equipped for 24-h urine collection. The
cages were in a quiet air-conditioned room (21°C) with a 12-h:12-h
light-dark cycle.
Continuous hemodynamic monitoring by telemetry. Each cage was
equipped with one RMC-1 receiver connected to a calibrated analog
adapter (R11CPA) and to an APR-1 barometric pressure reference
device. All devices were manufactured by Data Sciences Interna-
tional. The telemetered analog pressure signal was sampled at 500 Hz
for 5-s periods every 30 s, 24 h a day and processed by customized
algorithms for beat-to-beat analysis to extract mean arterial pressure
(MAP), systolic and diastolic blood pressures (SBP, DBP, respec-
tively), HR, rise time (time to reach peak SBP from the previous DBP
point), and maximum rate of change of arterial pressure (dPa/dt) (17).
Telemetry probes were calibrated before implantation and after re-
moval in a sealed pressure chamber at 0 and 200 mmHg, and pressure
values were linearly corrected according to calibration values (29).
Data were analyzed from 10:00 AM to 8:00 AM the next morning.
The period between 8:00 AM and 10:00 AM was used for daily
maintenance and was omitted from the analysis.
The computer program separated the 22-h data set into a series of
44 half-hour periods. The standard deviation (SD) of BP (for both
MAP and SBP) were calculated for each half-hour period. The mean
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SD of BP was used as a measure of the short-term variability of BP,
i.e., the extent of the variation in BP within half-hour periods (19, 30).
In addition, we also calculated the SD of the 44 half-hourly mean BP
values and used the SD as a measure of the long-term variability of
BP, i.e., the extent of the variation in BP between half-hour periods
(19, 30). Finally, the SD of all 2,640 daily samples was also computed
as an index of overall 22 h BPV. Similar calculations were performed
to calculate the short- and long-term HR variability. It should be noted
that the SD of HR within half-hour periods does not represent
beat-to-beat HR variability but the 30s-to-30s variability of HR. It is
thus labeled “short-term” HR variability.
Experimental protocol. In all rats, experimental measurements
included measurement of BP and HR 22 h a day and monitoring of
daily food, water, and sodium intakes, urine output, and sodium and
potassium excretions. Food and water intake were determined by
differential weighing (precision at 0.1 g). Urine was collected in a
graduated container. Urinary sodium and potassium concentrations
were determined by ﬂame photometry (model IL 943). All animals
had free access to tap water and were fed with a ﬁxed amount of 20 g
(slightly below the normal ad libitum intake) of standard rat chow per
day to ensure a ﬁxed sodium intake (a total of about 4 mmol/day,
including 2.2 mmol/day via the infusion).
In seven rats that were successfully instrumented (10.7  0.2 wk
old, weighing 396  14 g), a SMB (Sigma, Switzerland) intravenous
infusion was started after at least 12 days after the rats recovered from
surgery and an additional control period of 4 days. SMB was infused
for 12 days at increasing rates (0.3, 0.6, and 1.2 g kg1 min1 iv,
4 days at each dose, labeled as periods 1, 2, and 3). The progressive
increase in the SMB-infusion rate was chosen to ensure sustained
muscarinic blockade, since pilot studies in which SMB was infused at
the single dose of 0.3 g kg1 min1 for 10 days showed a higher
BP during the ﬁrst 4 days of infusion (approximately 10 mmHg)
than during the following days (approximately 5mmHg). The SMB
infusion was followed by a 10-day recovery period to test the
reversibility of the experimental changes. All solutions (SMB or
vehicle saline) were prepared aseptically and infused through a
0.22-m Millipore ﬁlter.
Because BP and HR are known to exhibit a small spontaneous
negative drift after surgery, a group of eight rats were submitted to the
same surgical procedures (telemetry, intravenous infusion) and
housed in identical cages to analyze the changes in BP and HR
occurring during vehicle time-control infusion from day 9 after
surgery (when the telemeter battery was turned on) up to 28 days after
surgery. In two rats, the arterial BP signal could not be used for
computation of MAP due to a large and unstable offset drift but was
adequate for the computation of HR. The rats were studied up to 4 wk
after surgery to quantify the spontaneous drift of the 22-h average of
BP and HR.
Statistical analysis. Each rat served as its own control, i.e., the
effects of SMB infusion were compared with the average of the 4
control days preceding SMB infusion. Statistical analysis was per-
formed by repeated measures ANOVA with the InStat statistical
package (GraphPad Software). Experimental and control values were
compared using Dunnett’s multiple comparison test. Changes were
considered signiﬁcant if P  0.05. Values are expressed as
means  SE.
RESULTS
SMB induced a rapid increase in mean, systolic and diastolic
pressures, and HR (Fig. 1). MAP peaked on day 2 of the SMB
infusion at 10.5  0.7 mmHg above a control value of
97.9  1.9 mmHg. The initial increase in MAP was attenuated
over the next few days but MAP remained signiﬁcantly ele-
vated at a plateau value of 2.9  0.7 mmHg (P  0.05)
during the last 4 days of SMB (period 3), as shown in Table 1.
On cessation of SMB infusion, MAP fell by 5.9  0.7 mmHg
(day 2 of recovery) and stabilized at 2.6  1.1 mmHg below
control value during the last 4 days of the recovery period
(days 7 to 10 after SMB cessation).
HR underwent an immediate increase with SMB infusion,
peaking on the ﬁrst day at 52  5 beats/min above the
control value of 345  8 beats/min. HR then tended to
decrease progressively but remained signiﬁcantly above con-
trol at22 5 beats/min by the last day of SMB infusion (day
12). After cessation of the SMB infusion, HR fell by 36  4
beats/min (day 2 of recovery). During the ﬁnal 4 days of the
recovery period, HR reached a value of 318 7 beats/min, i.e.,
27  6 beats/min below the control level.
Rats infused with vehicle infusion showed a small decrease
in MAP by 3.0  0.9 mmHg from 97.7  1.1 mmHg (average
of days 9–12 postsurgery) to 94.7  1.0 mmHg (average of
days 25–28), with most of the decrease (2.5  1.1 mmHg)
occurring during the ﬁrst 20 days after surgery. HR showed a
larger decrease of 31  5 beats/min from a control value of
361  9 beats/min (average of days 9–12 postsurgery), with
most of the decrease (22  5 beats/min) occurring during the
ﬁrst 20 days after surgery. Subtracting the average daily
negative drift of BP and HR observed in time-control rats
(using postsurgery days 13–16 as the control period) from
individual values of experimental rats, we estimate the actual
effects of SMB on MAP and HR in experimental rats to
amount to 10.2  0.4, 5.2  0.7, and 5.5  0.7 mmHg for
periods 1, 2, and 3, respectively, and to 60  5, 53  4, and
47  4 beats/min for the same periods.
Daily values of pulse pressure (PP), maximum dPa/dt, and
rise time in SMB-infused rats are shown in Fig. 2. Changes
from control values are summarized in Table 1. PP and max-
imum dPa/dt were signiﬁcantly higher only during the ﬁrst few
days of infusion (on day 3, PP peaked at 3.5  0.7 mmHg
above the control value of 22.8  1.4 mmHg and maximum
dPa/dt peaked at 840  216 mmHg/s above a control value
of 5,062  306 mmHg/s). Rise time was signiﬁcantly
shorter during days 1–4 (period 1) and 5–8 (period 2) and
tended to remain shorter during the last 4 days of SMB
infusion (period 3).
Daily values of short-term and long-term MAP and HR
variabilities are shown in Fig. 3. SMB induced a progressive
increase in both short-term (16%, last 4 days of SMB
infusion) and long-term (36%) MAP variabilities, which
reverted progressively to control values on cessation of the
SMB infusion. Interestingly, the changes in long-term variabil-
ity were slower to appear and also to disappear. The increase in
BP variability was signiﬁcant for both MAP and SBP and for
all three indexes of variabilities (within 30 min SD , between
30 min SD, and overall 22 h SD), as shown in Table 2. SMB
also lead to a marked (43%) and sustained decrease in
short-term HR variability (HRV). In contrast, the decrease in
long-term HRV was only transient (25% on day 2).
Total water intake and urinary output tended to increase
progressively during SMB infusion, as shown on Fig. 4 and
were signiﬁcantly higher during the last 4 days of infusion
(water intake:  7.2 ml from a control value of 37.8  1.1
ml/day; urine output:8.6 ml from control value of 24.7 0.7
ml/day). Both variables returned slowly toward control during
the recovery period. Changes occurred in parallel and, as a
consequence, daily water balance remained unaltered. In 3 of 7
rats, food intake (ﬁxed at a maximum of 20 g/day) decreased
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slightly on day 2 of SMB infusion but was back to normal
thereafter. This explains the transient decrease in sodium and
potassium intakes during day 2. In these three rats the non-
ingested sodium of day 2 was compensated on the next day by
supplementing food with an estimated equivalent of sodium
chloride. Sodium and potassium balances remained stable over
the following days.
DISCUSSION
Whereas numerous studies have reported the cardiovascular
effects of acute parasympathetic inhibition, we are not aware of
any published study of the effects of more sustained parasym-
pathetic blockade on hemodynamic function. The main ﬁnding
of our study is that chronic peripheral muscarinic blockade
leads to signiﬁcant hemodynamic alterations, including sus-
tained elevations in BP, HR, and BPV.
The effect on BP was most pronounced during the ﬁrst 3
days of muscarinic inhibition, with a peak increase in SBP,
MAP, and DBP of more than 10% during day 2 of SMB.
Although BP tended to return toward control level over the
following few days, BP remained signiﬁcantly elevated during
the last 4 days of SMB infusion as shown in Table 1, a
conclusion also supported by the off transient in BP when the
infusion was halted. The chronic SMB-induced effect on MAP
amounted to a 3–6% increase, depending whether its effects
are compared with the initial control period (3%) or the ﬁnal
recovery period (6%).
The partial recovery of blood pressure during SMB infusion
occurred despite evidence of the continued effectiveness of
muscarinic blockade by SMB. HR, which initially increased by
as much as 15% above control value, remained elevated by
11% on the last day of SMB infusion (based on the size of the
Fig. 1. Effects of a 12-day scopolamine methyl
bromide (SMB) infusion on mean arterial pressure
(MAP), systolic blood pressure (SBP), and diastolic
blood pressure (DBP), and on heart rate (bpm, beats/
min).
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off transient, day 2 of recovery). The attenuation of the “short-
term” HR variability was even more dramatic, responding
promptly at the onset and end of SMB infusion and not
wavering throughout the 12-day infusion period. Combined
with the observation that doubling the SMB dosage on days
5–8 (period 2) and again on days 9–12 (period 3) failed to
cause further alterations in HR, “short-term” HR variability, or
any other measured parameter, our data suggest that the SMB
infusion provided an effective and sustained blockade of car-
diac muscarinic receptors.
The values of BP and HR during days 7–10 of the recovery
period (2.6  1.1 mmHg and 27  6 beats/min below
control values for MAP and HR, respectively) are consistent
with a moderate spontaneous decrease in hemodynamic values
often observed in chronic experiments after a surgical proce-
dure. Indeed, in a group of vehicle-infused rats instrumented in
a similar way, there was an average decrease in MAP and HR
of 3% and 8%, respectively, from days 9–12 after surgery to
days 25–28. This slow decrease in vehicle-infused animals,
possibly related to the gradual disappearance of expected
postsurgery inﬂammatory reactions, strengthens our ﬁndings in
SMB-infused rats that the signiﬁcant increases in MAP and HR
associated with long-term SMB infusion are not due to a slow
positive baseline drift but represent a real phenomenon.
Indeed, after the negative drift occurring in time-control
animals was corrected, the estimated chronic effects of SMB
amounted to a 6% increase in MAP and a 13% increase in
HR (period 3).
Fig. 2. Effects of a 12-day SMB infusion on pulse pressure,
maximum arterial pressure change rate (dPa/dt) and rise
time.
Table 1. Changes in hemodynamic values when compared with control levels
Variable Period 1 Period 2 Period 3 Recovery
SBP, mmHg 9.30.5† 3.50.9* 3.31.1* 2.81.6
MAP, mmHg 8.20.4† 3.30.7† 2.90.7* 2.61.1*
DBP, mmHg 6.70.5† 2.90.7* 2.50.5* 20.9
HR, beats/min 475† 354† 244† 276†
PP, mmHg 2.60.7* 0.70.8 0.81 0.81.5
Max dPa/dt, mmHg/s 579184* 185163 66264 138260
Rise time, ms 1.70.2* 1.30.4* 1.00.4 0.21
Values are means  SE (n  7 rats) computed as changes from control levels 	last 4 days before starting scopolamine methyl bromide (SMB) infusion
. SBP,
systolic blood pressure; MAP, mean arterial pressure; DBP, diastolic blood pressure; HR, heart rate; PP, pulse pressure; Max dPa/dt, maximum rate of change
of arterial pressure. Periods 1, 2, and 3 correspond to days 1–4, 5–8, and 9–12, respectively, of SMB infusion. Recovery corresponds to days 7-10 after cessation
of SMB infusion.*P  0.05 and †P  0.01 vs. control period (Dunnett’s).
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Although our experimental approach (recording throughout
the day, with animals left undisturbed as much as possible) did
not allow a more precise determination of the mechanisms
underlying the SMB-induced increase in BP, at least three
factors could be involved: 1) an increase in cardiac output (CO)
due to a primary increase in HR and/or stroke volume; 2) an
increase in peripheral vascular resistance; and 3) an altered
ability of the kidney to excrete salt and water.
For the ﬁrst factor, while an increase in HR is expected
initially to increase CO, stroke volume tends to fall with time
and changes in HR per se may not lead to sustained increases
in CO (8). However, a combination of increased HR and
contractility could potentially cause a larger increase in CO.
Tachycardia alone is expected to decrease PP and maximum
dPa/dt as shown in heart-pacing experiments (26). In our
experiments, the observed increases (and the lack of decreases)
in PP and maximum dPa/dt and the decrease in rise time are
consistent with an increase in cardiac contractility during the
SMB infusion, although we cannot exclude an effect of SMB
to decrease arterial distensibility.
For second factor, muscarinic blockade could promote va-
soconstriction. There is, however, little vascular parasympa-
thetic innervation to be blocked except for sparse specialized
circulations (33), but there is evidence for a local release of
acetylcholine (ACh) by endothelial cells themselves. The pres-
ence of choline acetyltransferase, the enzyme responsible for
the synthesis of ACh, has been shown in cerebral microvascu-
lar endothelial cells of rats (20) and pigs (11), as well as in
bovine carotid artery endothelial cells (13). Milner et al. (16)
could demonstrate a local release of ACh in isolated human
umbilical vein endothelial cells, which is triggered by shear
stress. Release of ACh by cultured endothelial cells prepared
Fig. 3. Effects of a 12-day SMB infusion on short-term and long-term MAP and heart rate (HR) variabilities. The time course of short-term and long-term SBP
variabilities was very similar to the time course of MAP variabilities and is therefore not shown.
Table 2. Short-term (within 30 min), long-term (between 30 min), and overall (22 h) SD of SBP and MAP
Variable Control Period 1 Period 2 Period 3 Recovery
SBP
Short-term SD, mmHg 4.90.3 5.60.2* 5.90.2† 5.70.2† 4.80.2
Long-term SD, mmHg 4.50.3 5.00.3 5.90.4† 6.30.6† 4.90.4
Overall SD, mmHg 6.60.3 7.50.2* 8.30.4† 8.50.5† 6.90.4
MAP
Short-term SD, mmHg 4.60.3 5.10.2* 5.40.2† 5.30.1† 4.50.2
Long-term SD, mmHg 4.10.3 4.50.2 5.30.4† 5.60.5† 4.50.3
Overall SD, mmHg 6.10.3 6.80.2* 7.50.3† 7.70.4† 6.30.3
Values are means  SE (n  7 rats). SD, standard deviation. Control represents the last 4 days before starting SMB infusion. Periods 1, 2, and 3 correspond
to days 1–4, 5–8, and 9–12, respectively, of SMB infusion. Recovery corresponds to days 7–10 after cessation of SMB infusion.*P  0.05 and †P  0.01 vs.
control period (Dunnett’s).
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Fig. 4. Effects of a 12-day SMB infusion on the daily
balance of water, sodium, and potassium. Water intake
and sodium intake include the amount of water and
sodium, respectively, contained in the intravenous infu-
sion. Balance was computed as intake minus urinary
excretion.
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from bovine carotid artery was veriﬁed by radioimmunoassay
(13). Taken together, these results show that endothelial cells
can synthesize and release ACh, which may act as an autacoid
and reinforce stretch-induced nitric oxide (NO) release. Inhi-
bition of endothelial muscarinic receptors by SMB may thus
impair stretch-induced NO release. Interestingly, the hyperten-
sive effect of NO synthase inhibition is potentiated by acute
cholinergic blockade (14), suggesting an interaction between
cholinergic and nitrergic vasodilatation.
For the third factor, the kidneys may also be involved in the
SMB increase in BP. Normally, a rapid increase in BP by
vasoconstrictors would be expected to result in a pressure-
induced natriuresis (10). Yet, no initial natriuresis was ob-
served in our experiments despite a rise in BP of more than 10
mmHg, suggesting sodium-retaining forces that could offset
pressure-induced natriuresis. ACh has a natriuretic effect on
the kidney, which is inhibited by atropine (34). Although there
is no clear parasympathetic innervation of the kidneys (5), the
antagonism of endothelial mechanisms, as described above,
could possibly promote renal vasoconstriction and sodium
retention.
Finally, ACh is known to inhibit the release of norepineph-
rine from sympathetic nerve terminals via stimulation of
prejunctional muscarinic receptors (36). Thus an additional
possibility is that blockade of these receptors by SMB could
effectively increased sympathetic tone at the level of the heart
and vasculature.
Although a chronic increase in 24 h BP of 3–6% is physi-
ologically relatively modest, human clinical trials indicate that
sustained similar increases in BP would have substantial ef-
fects on cardiovascular risk. Furthermore, it is possible that the
tonic inﬂuence of the parasympathetic nervous system on BP
may play a larger role in humans or in other circumstances.
Indeed, rats have a modest parasympathetic tone compared
with larger animals such as dogs and humans, perhaps in part
because they are usually studied at laboratory temperatures
(20–22°C), which are well below the range of ambient
temperatures that requires minimal thermoregulatory effort to
maintain body temperature (thermoneutrality zone). The ther-
mal neutral zone of healthy rats of common strains in experi-
mental setups similar to ours (single cage housing, no bedding)
is around 30°C (23). Warming ambient temperature into the
zone of thermoneutrality has been shown to reduce BP and HR
and to increase HR variability in both rats and mice (28). The
parasympathetic system may thus play a potential larger role in
BP regulation in humans than in rats and mice maintained at
standard laboratory temperatures.
Chronic muscarinic blockade also led to signiﬁcant increases
in short-term (within 30 min SD), long-term (between 30 min
SD), and overall (22 h SD) BPV. Vagal dysfunction impairs
the baroreﬂex control of HR, which in turn could lead to
greater oscillations in BP and hence to an increased short-term
BPV (7). Indeed, muscarinic blockade in our study led to a
marked and sustained decrease in “short-term” HR variability
and an increase in short-term BPV. The slow increase in
long-term BPV observed during SMB infusion is intriguing,
but the underlying mechanism remains unclear.
Increases in BPV could contribute to hypertensive target
organ damage (TOD). Indeed, several clinical investigations
have found TOD to be more advanced in patients with in-
creased BPV (19, 21). These ﬁndings have been reinforced by
a prospective investigation (9) in which patients that had taken
part in one of the original studies (19) were followed up 7
years later. The role of systolic BPV in promoting TOD has
been conﬁrmed in large clinical studies, such as the Pressioni
Arteriose Monitorate E Loro Associazioni (PAMELA) study
(25) and the Syst-Eur trial (22).
Perspectives. Parasympathetic dysfunction is not a rare
event. In addition to hypertension itself, reductions in cardiac
parasympathetic tone or reactivity have been described in
obesity (1, 31), diabetes mellitus (3), chronic renal failure (2),
physical inactivity (24), and ageing (27). Other factors may
promote parasympathetic dysfunction via direct muscarinic
receptor inhibition. Autoantibodies against muscarinic recep-
tor, of which its occurrence increases with age, have been
found in healthy subjects (15). Moreover, some major drugs,
such as neuroleptics, antiarrhythmics, and antidepressants may
have anticholinergic effects.
Whereas a contribution of parasympathetic dysfunction to
cardiovascular morbidity has been suggested by many authors,
the hemodynamic effects of chronic muscarinic blockade have
not been reported. Our study shows that chronic muscarinic
receptor inhibition favors a small increase in BP and leads to a
signiﬁcant increase in both short-term and long-term BPV. Our
data suggest that chronic peripheral muscarinic blockade could
contribute to the development or aggravation of hypertension
and TOD.
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